Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies

Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies

Post hoc analyses of 9-valent human papillomavirus (9vHPV) vaccine immunogenicity were conducted in five Phase 3 studies that enrolled males. Month 7 antibody geometric mean titers (GMTs) after three 9vHPV vaccine doses were analyzed in 10,024 males/females aged 16–26 years from studies 001 (NCT0054...

Full description

Saved in:
Bibliographic Details
Main Authors: Anna R. Giuliano, Joel M. Palefsky, Stephen E. Goldstone, Jacob Bornstein, Ilse De Coster, Ana María Guevara, Ole Mogensen, Andrea Schilling, Pierre Van Damme, Corinne Vandermeulen, Misoo C. Ellison, Susan Kaplan, Jianxin Lin, Rachael Bonawitz, Alain Luxembourg
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
9-valent HPV vaccine
human papillomavirus
immunogenicity
males
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2425146
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items